Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
David Mulllins
Dartmouth College, Department: Microbiology/immun/virology
Should you be removed from our database? Contact us at [email protected]. Read more below.
Qu Biologics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
This project will evaluate the ability of a proprietary compound of Qu Biologics to enhance the ability of other therapies infiltrate tumors, and thereby serve as a more effective "combination" therapy against certain cancers. In light of Prof. Mullins’s position as Chief Scientific Officer of Qu Biologics (and compensation associated with this role) as well as his equity interest in the company and his role as PI in this project, our Conflict of Interest Committee has determined that his financial interest in Qu Biologics could significantly and directly affect the design, conduct, and reporting of the research.
Combinational Therapy of Melanoma using T Cells and site-specific Immunomodulators
The clinical efficacy of T cell-based immunotherapy is limited, in part, by the relatively poor efficiency of lymphocytic infiltration into tumors. Our preliminary data suggest that bacteria- based site-specific immunomodulators (SSI), a proprietary compound developed by Qu Biologics, may modulate the chemotactic milieu of the tumor microenvironment to favor T cell infiltration, albeit through an unknown mechanism. We will evaluate whether subcutaneous administration of specific SSIs can induce or enhance the production of cytokines and key chemokines in the tumor microenvironment and thereby increases T cell infiltration and immunologic control of melanomas.
Filed on April 03, 2015.
Tell us what you know about David Mulllins's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “David Mulllins”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| David Mulllins | Dartmouth College | Conflict of Interest | Qu Biologics | $20,000 - $39,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.